This multi-cohort, prospective, nationwide registry study will enroll newly diagnosed oligometastatic HER2+ breast cancer patients.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Working under the hypothesis that a subset of de novo oligometastatic breast cancer patients who are treated with a combination of systemic therapy, surgery, and radiation or ablation of metastatic sites will have long-term distant metastasis free and overall survival, this multi-cohort, prospective, nationwide registry study will enroll newly diagnosed oligometastatic (operationally defined by local tumor boards as disease where all metastatic lesions can be ablated) HER2+ breast cancer patients. Using an online portal, physicians can download a consent form, register patients, receive a multimodality treatment pathway that can potentially cure a subset of these patient, and enter information regarding what treatment the patient received, follow up, and outcomes information. The portal also gives patients access to input quality of life and patient reported outcome measures.
Mariya Rozenblit, MD
Assistant Professor of Medicine
Yale School of Medicine
“Registry trials are helpful because they represent real-world data…So, for example, our trial is an online registry trial. All the information is collected online, so no one has to travel. And there’s no criteria for participation except that you must have this specific type of breast cancer...We’re hoping that by offering this clinical trial online, we can have a much more diverse patient population participating. We are hoping to get community practices from all over the country because there are less barriers to participation.”
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
